Table 1.
Characteristics of participants with preserved pulmonary function and with airflow obstruction
| |
Preserved Pulmonary Function* |
Airflow Obstruction* |
|---|---|---|
| (n = 100) | (n = 476) | |
| Demographics | ||
| Age, yr | 66.5 (10.6) | 67.8 (9.5) |
| Sex, % women | 36 (36.0) | 181 (38.0) |
| Race, % nonwhite | 18 (18.0) | 90 (18.9) |
| Comorbidities and general health | ||
| Sleep apnea status, % | ||
| No sleep apnea | 62 (62.0) | 378 (79.4) |
| Sleep apnea, nonadherent to CPAP/untreated | 28 (28.0) | 77 (16.2) |
| Sleep apnea, adherent to CPAP | 10 (10.0) | 21 (4.4) |
| Depression diagnosis, % | 58 (58.0) | 177 (37.2) |
| Diabetes mellitus, % | 33 (33.0) | 102 (21.43) |
| Chronic kidney disease, % | 25 (25.0) | 84 (17.7) |
| Coronary disease, % | 47 (47.0) | 175 (36.8) |
| Heart failure, % | 20 (20.0) | 74 (15.6) |
| Sciatica, % | 59 (59.0) | 195 (41.0) |
| Number of comorbidities | 5.7 (2.8) | 4.5 (2.4) |
| BMI, kg/m2 | 30.8 (6.1) | 28.7 (7.0) |
| Sleep disturbance, T-score | 54.2 (9.9) | 50.0 (9.5) |
| Depression, T-score | 50.5 (9.4) | 48.6 (9.3) |
| Anxiety, T-score | 52.2 (9.4) | 50.0 (9.0) |
| Pain interference, T-score | 58.7 (8.6) | 54.0 (9.5) |
| 6-Minute walk distance, ft | 1,089 (390) | 1,112 (349) |
| Respiratory health | ||
| FEV1 % predicted | 94.8 (15.1) | 58.3 (18.9) |
| Hypoxemia status, % | ||
| Nonhypoxic | 81 (85.3) | 260 (56.8) |
| Hypoxemic, using oxygen | 11 (11.6) | 159 (34.7) |
| Hypoxemic, without oxygen | 3 (3.2) | 39 (8.5) |
| FACIT dyspnea, score | 44.4 (8.0) | 44.7 (8.0) |
| Currently smoking, % | 35 (35.0) | 165 (34.7) |
| Respiratory medications | ||
| LABA, % | 13 (13.0) | 164 (34.5) |
| LAMA, % | 5 (5.0) | 149 (31.3) |
| SABA, % | 41 (41.0) | 269 (56.5) |
| SAMA, % | 16 (16.0) | 106 (22.3) |
| ICS, % | 18 (18.0) | 208 (43.7) |
| Systemic corticosteroid, % | 1 (1.0) | 14 (2.9) |
Definition of abbreviations: BMI = body mass index; CPAP = continuous positive airway pressure; FACIT = Functional Assessment of Chronic Illness Therapy; ICS = inhaled corticosteroid; LABA = long-acting β-agonist; LAMA = long-acting muscarinic antagonist; SABA = short-acting β-agonist; SAMA = short-acting muscarinic antagonist.
P value from χ2 or unpaired t test for categorical or continuous variables, respectively.
*
Values shown represent mean (SD) or n (%).